Asociación de Eventos Adversos Relacionados con el Sistema Inmunitario con la Eficacia de Nivolumab en Cáncer de Pulmón No Microcítico

Haratani et al. (Tue,) estudiaron esta cuestión.

www.synapsesocial.com/papers/69d74e0cb1cb92dd1bb8a666 — DOI: https://doi.org/10.1001/jamaoncol.2017.2925

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer· 2016 · 116 citations
2. Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis· 2015 · 612 citations
3. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab· 2015 · 646 citations
4. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective study· 2016 · 221 citations
5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer· 2015 · 9,421 citations